Introduction {#sec1-1}
============

Disorders of sex development (DSD) refer to congenital conditions in which development of chromosomal, gonadal or anatomical sex is atypical.\[[@ref1]\] Among DSDs, some of them are expressed as congenital condition while in others it may be manifested during puberty due to hormonal rage. Clinical presentation observed in patients with DSD ranges from ambiguous genitalia to complete female phenotype. Patient with DSD may have dysgenetic wolffian structure such as dysgenetic testes, mild to severe penoscrotal hypospadias with or without chordee; whereas the dysgenetic mullerian structure can also be observed that ranges from absence to the presence of a fully developed uterus and fallopian tubes.

Among chromosomal abnormalities, DSDs are determined by presence/absence or numerical abnormality of sex chromosome (X and Y). However some of the conditions are due to single gene disorder. *SRY* gene present in the Y chromosome is the major male sex determining gene. Although the female development was thought to be a default in the absence of *SRY* (or Y chromosome); however in recent studies, it has been discovered that the presence of DAX1 gene on X chromosome accounts for female phenotype in mice.\[[@ref2]\] Gonadal sex determination takes place when the bipotential gonadal ridge turns into either testes or ovaries. The process starts around 4^th^ week and ends by 12^th^ week of pregnancy and is directed in a critically timed and gene dosage dependent manner. *SRY* gene stimulates the bipotential gonadal ridge to develop into testes. Testes produce two hormones testosterone and anti-mullerian hormone (AMH). Testosterone and its derivative dihydrotestosterone induce the formation of wolffian structures while AMH degenerates the mullerian duct; therefore, manifests male phenotype. In females (46, XX) who do not possess the *SRY* gene, the ovary forming pathway is activated by a different set of proteins. The fully developed ovary then produces estrogen which triggers the development of uterus, oviducts and cervix from the mullerian duct. Along with *SRY* gene, various autosomal and sex-linked genes such as *SOX9*, *WT1*, steroidogenic factor-1 (*SF1*), *AR*, *DHH* and *MAP3K1* are also known to be involved in the process of sex development of the fetus.

Our present study is focused on identification of mutations in mitogen activated protein kinase kinase kinase 1 (*MAP3K1*) gene that belongs to MAPK family of genes, which is known to be involved in transmitting signals generated at the cell surface into the cytosol and nucleus.\[[@ref3]\] MAPKs comprise a family of ubiquitous proline-directed, protein-serine/threonine kinases, which participate in signal transduction pathways that control intracellular events including acute responses to hormones and major developmental changes in organisms.\[[@ref4]\] Recently, *MAP3K1* was first associated with 46,XY DSD by Pearlman *et al*.\[[@ref5]\] However, Warr *et al*. has demonstrated from their studies that *MAP3K1* has insignificant role in testis determination of mice.\[[@ref6]\] Taking into consideration that the *MAP3K1* gene is required for development, therefore, *MAP3K1* is one of the suspected genes that might cause downstream alterations in development of sex in humans. In this study, mutation analysis of *MAP3K1* gene was carried out in 10 cases of DSD.

Materials and Methods {#sec1-2}
=====================

 {#sec2-1}

### Patients {#sec3-1}

All patients screened in this study were sporadic. 10 patients with 46,XY DSD were selected for the study. Patients were classified according to gender identity disorder in children listed under Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The clinical presentations of all the patients were given in [Table 1](#T1){ref-type="table"}.

###### 

Clinical presentation of 46,XY DSD patients along with the gender assignment and karyotype

![](IJHG-19-437-g001)

### Genomic deoxyribonucleic acid isolation and polymerase chain reaction amplification {#sec3-2}

Whole blood samples from patients and controls were collected in EDTA/K2 BD Vacutainer^®^ tubes (Becton Dickinson and Company, NJ, USA). Genomic DNA was isolated from 2.0 ml of blood collected from the above patients using QIAmp DNA extraction kit (Qiagen, GmBH, Germany). PCR amplification was performed using Takara Hot Start PCR kit in 50 μl of ×10 Ex Taq^™^ buffer (contains 20 mM MgCl~2)~, 10 mM deoxyribonucleotide triphosphate mixture (2.5 mM of each deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate and deoxythymidine triphosphate), ×2.5 GC solution, 25 pmol primers, 250 ng template DNA and 1.5 units of Taq^™^ HS DNA polymerase. All the 21 exons were amplified separately using specific primers designed from the wild-type *MAP3K1* sequence. PCR was cycled 35 times; each cycle consisted of denaturation for 1 min at 94°C, annealing for 45 min at 53-69°C and extension for 1 min at 72°C. After amplification, 3 μl of PCR product was subjected to electrophoresis on 2% agarose gel for 45 min at 100 V in tris-acetate-EDTA buffer and bands were stained with ethidium bromide (0.5 mg/ml).

### Sequencing and analysis of sequence {#sec3-3}

The PCR products were gel purified using QIAquick Gel extraction kit (QIAGEN, GmBH, Germany) according to manufacturer\'s protocol. The gel purified PCR products were sequenced using gene specific primers on ABI PRISM 3130xl version 3.1 DNA sequencer (Applied Biosystems, Foster City, CA, USA). The sequences were analyzed for the presence of mutations using Lasergen program (DNASTAR, Inc., Madison, USA). Multiple sequence alignment was carried out using MegAlign program of DNASTAR and WebLogo was created using online software (<http://weblogo.berkeley.edu/WebLogo>: A Sequence Logo Generator).

Results {#sec1-3}
=======

Genomic DNA was isolated from patients and control blood samples and the integrity was checked by running on 0.8% agarose gel electrophoresis. The purity was checked by A~260~/A~280~ and was found to be 1.8, which suggests the good quality of genomic DNA.

All the 20 coding regions including exon-intron boundary of *MAP3K1* gene were amplified using gene specific primers and sequenced using automated DNA sequencer. Upon sequence analysis, a total of four different sequence variants including one missense, two silent and one insertion have been identified. The missense mutation (c.2416 G \> A p.D806N; rs702689) was identified in exon 14 \[[Figure 1a](#F1){ref-type="fig"}\] of *MAP3K1* gene in four patients (2-4 and 7). The silent mutation (c.3084A \> G p.Q1028Q; rs3822625) was also identified in patient 6 present in exon 14 \[[Figure 1b](#F1){ref-type="fig"}\]; whereas the other silent mutation (c. 1284G \> A p.T428T; rs832575) was identified in exon 6 \[[Figure 1c](#F1){ref-type="fig"}\] in patient 10. Two patients (8 and 10) were found to have insertion mutation (c. 2822_2824insCAA p.T942ins; rs34869245) present in exon 14 \[[Figure 1d](#F1){ref-type="fig"}\] of *MAP3K1* gene.

![Deoxyribonucleic acid sequence chromatogram showing the presence of mutations. (a) p.D806N mutation in exon 14 of mitogen activated protein kinase kinase kinase 1 (MAP3K1) gene. This is a heterozygous mutation indicated by an arrow showing presence of two overlapping peaks corresponding to two nucleotides A (wild type) and G (mutant) (b) p.Q1028Q mutation in exon 14 of MAP3K1 (c) p.T428T heterozygous mutation in exon 6 of MAP3K1 (d) p.T942ins mutation in exon 14 of MAP3K1 showing insertion of CAA nucleotide triplet. The chromatogram for this mutation has been reverse complemented for which the frameshift has been depicted toward left](IJHG-19-437-g002){#F1}

*In-silico* analysis of p.D806N missense mutation has been carried out to find out the importance of the residue. Multiple sequence alignment was carried out with its homologs retrieved from NCBI database and those include amino acid sequences of *Homo sapiens* (Accession No. NP_005912.1), *Gorilla gorilla gorilla* (XP_004058877.1), *Pan troglodytes* (XP_003310777.1), *Pongo abelii* (XP_002815621.1), *Ailuropoda melanoleuca* (XP_002928301.1), *Macaca mulatta* (XP_002804414.1), *Nomascus leucogenys* (XP_003266148.1), *Callithrix jacchus* (ABY79119.1), *Bos taurus* (NP_001192835.1), *Equus caballus* (XP_001916604.1), *Canis lupus familiaris* (XP_535240.4), *Sus scrofa* (XP_003134021.1), *Felis catus* (XP_003981022.1), *Gallus gallus* (XP_424734.3), *Mus musculus* (NP_036075.2), *Anolis carolinensis* (XP_003216255.1), *Rattus norvegicus* (NP_446339.1), *Callicebus moloch* (ACA57887.1), *Dasypus novemcinctus* (ACO15795.1), *Monodelphis domestica* (XP_001381167.1), *Oryctolagus cuniculus* (ACJ73998.1), *Otolemur garnettii* (XP_003782799.1), *Taeniopygia guttata* (XP_004175671.1) and *Rhinolophus ferrumequinum* (ACC62498.1). The WebLogo was also created using online software (<http://weblogo.berkeley.edu/WebLogo>: A Sequence Logo Generator). Both multiple sequence alignment and weblogo revealed that the p.D806N was well conserved across species \[Figure [2a](#F2){ref-type="fig"} and [2b](#F2){ref-type="fig"}\]. The polyphen analysis (<http://genetics.bwh.harvard.edu/pph2/>) was also carried out and the score for this missense mutation was found to be 0.999.

![Multiple sequence alignment with the homologues from different species showing the extent of conservation at the mutation site. (a) A multiple sequence alignment of p.D806N mutation showing the conserved aspartate (D) across species (highlighted by red shaded box) (b) WebLogo showing the conservation of p.D806N mutation showing the conserved aspartate (D) residue indicated by highlighted area](IJHG-19-437-g003){#F2}

Discussion {#sec1-4}
==========

DSD consist of a wide range of disorders and are more common in those with an XY karyotype.\[[@ref7]\] The most widely used method to find out the genetic abnormality in 46,XY DSD cases is by sequencing the exonic region of suspected genes and to analyze those for the presence of mutation/s. In this study, mutation analysis in all exonic regions of *MAP3K1* gene was carried out in a cohort of 10 patients including one family with two affected sisters.

Several sex chromosomal and autosomal genes are responsible for sexual development. In our earlier study, two homozygous mutations in the Desert hedgehog (*DHH*) gene were reported. Two mutations were a homozygous deletion (c. 271_273delGAG) that resulted in a deletion of one amino acid (p.D90del) and a homozygous duplication (c. 57-60dupAGCC) that resulted in premature termination resulting in non-functional *DHH* protein. Structural studies on the p.D90del mutant revealed that the mutation could seriously perturb the interaction of *DHH* with its binding partners.\[[@ref8]\]

Patients involved in present study were already screened for *SRY*, *SF1* and *DHH* gene and were found to have no mutations in any of the above genes. *MAP3K1* gene is known as a member of the MEK/ERK signaling pathway. MAPK cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation. An aberrant regulation of MAPK cascades is known to contribute to cancer and other human diseases.\[[@ref9]\] However recently, *MAP3K1* was associated with 46,XY DSD in a study where a linkage analysis on long arm of chromosome five was carried out in 46,XY DSD patients from two families and 11 sporadic cases. *MAP3K1* expression was also observed throughout the mouse embryonic gonad at 11.5 dpc which is the sex-determining stage of gonad development. Staining was observed within the testis cords at 13.5 dpc in a pattern indicative of Sertoli cell expression.\[[@ref5]\] However, despite of observing minor abnormalities in testis development in mice lacking *MAP3K1* gene, Warr *et al*. concluded that *MAP3K1* has no significant role for mouse testis determination.\[[@ref6]\]

In four of our patients, a missense mutation p.D806N was identified in exon 14 which of caused replacement aspartic acid (D) by aspargine (N) at position number 806 in amino acid sequence. aspartic acid is an acidic amino acid present in the wild *MAP3K1* replaced by asparagine, neutral and polar amino acid. Due to change in the polarity, the secondary structure of the protein may be affected. Multiple sequence alignment and Weblogo revealed that the amino acid Aspartate (D) at position 806 is highly conserved across species. This phylogenetically conserved residue indicated the importance of this residue in structure and function of the protein. The pathogenicity of this mutation was tested using polyphen and the score was found to be 0.999, indicating high probability of pathogenic mutation. Genotype-phenotype correlation of this mutation have been carried out and found that all the patients with this mutation had hypospadias with associated gonadal abnormality. However, interestingly this missense mutation was found to be a polymorphism in NCBI SNP database. The significant association of this mutation have been shown to be associated with asthma.\[[@ref10]\] However, genital abnormality with this polymorphism has not been reported.

A silent mutation (p.Q1028Q) was identified on exon 14 of *MAP3K1* in patient 6. Clinical presentation of this patient had bilateral, well-developed, palpable gonads with ambiguous genitalia. Since, the mutation does not change the amino acid, thus may not affect protein structure.

In another patient, two mutation comprising of one deletion mutation (p.T942ins) and silent mutation (p.T428T) were identified in patient 10. The clinical presentation of this patient was observed like androgen insensitivity syndrome (no mutation in AR gene). In addition, the deletion mutation (p.T942ins) was also present in patients 8.

Conclusion {#sec1-5}
==========

We have identified four sequence variants in *MAP3K1* gene including one missense mutation, two silent mutations, and a deletion mutation. All the mutations were found to be polymorphism upon comparing to dbSNP. However, *in-silico* analysis of the missense mutation revealed to be a pathogenic mutation. Further in-vitro analysis would confirm the damaging effect of this mutation. In this report, we reported mutation/polymorphism that may not be directly associated with the sexual development. However, large case-control study is required for establishing the involvement of *MAP3K1* in the development of genital ambiguity.
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